List of Excipients in Branded Drug IMCIVREE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rhythm Pharmaceuticals Inc	IMCIVREE	setmelanotide	72829-010	BENZYL ALCOHOL	2034-07-04
Rhythm Pharmaceuticals Inc	IMCIVREE	setmelanotide	72829-010	CARBOXYMETHYLCELLULOSE	2034-07-04
Rhythm Pharmaceuticals Inc	IMCIVREE	setmelanotide	72829-010	EDETATE DISODIUM	2034-07-04

IMCIVREE Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Imcivree is a differentiated commercial opportunity for excipient, packaging, delivery-device, and formulation suppliers because it treats rare genetic obesity with chronic subcutaneous dosing in adults and children. The marketed product is a sterile aqueous setmelanotide injection containing benzyl alcohol, citrate buffer components, hydrochloric acid, and water for injection. The strongest opportunities are preservative-free pediatric presentations, pen or cartridge delivery, lower injection burden, improved cold-chain stability, and formulation or device patents that extend commercial differentiation beyond the active ingredient.

What is Imcivree and how is it formulated?

Imcivree contains setmelanotide, a melanocortin-4 receptor agonist developed by Rhythm Pharmaceuticals. The U.S. Food and Drug Administration approved Imcivree in November 2020 for chronic weight management in adults and children aged 6 years and older with obesity caused by genetically confirmed POMC, PCSK1, or LEPR deficiency. FDA expanded the indication to include Bardet-Biedl syndrome in 2022 and lowered the minimum age to 2 years for the relevant genetic obesity indications.[1,2]

The commercial product is a 10 mg/mL sterile subcutaneous injection supplied in a multidose vial. The U.S. prescribing information identifies the inactive ingredients as benzyl alcohol, citric acid monohydrate, sodium citrate dihydrate, hydrochloric acid, and water for injection.[3]

Product attribute	Imcivree characteristic
Active ingredient	Setmelanotide
Pharmacologic class	MC4R agonist
Dosage form	Sterile subcutaneous injection
Strength	10 mg/mL
Primary container	Multidose vial
Preservative	Benzyl alcohol
Buffer system	Citric acid and sodium citrate
pH adjustment	Hydrochloric acid
Administration	Subcutaneous injection
Key populations	Pediatric and adult patients with rare genetic obesity
Regulatory pathway	New drug application, not a biologic license application

The excipient system is commercially important because treatment is chronic, pediatric use is central, dosing is weight-based, and the product is administered at home. Those conditions increase the value of dose accuracy, low injection volume, storage flexibility, and ease of use.

What excipients are used in Imcivree?

Benzyl alcohol

Benzyl alcohol is the preservative in the marketed multidose presentation. It supports repeated withdrawals from the vial and reduces the risk of microbial proliferation during in-use storage.

Its presence creates several formulation and commercial constraints:

• Pediatric toxicology must remain acceptable for the approved age range.
• The product must carry appropriate restrictions for neonates and very young infants, even though those populations are outside the core indication.
• Compatibility with elastomeric stoppers, needle components, and delivery devices requires testing.
• Regional requirements for preservative exposure may influence formulation strategy.
• A preservative-free presentation could create a differentiated product rather than merely a lower-cost substitute.

A preservative-free, single-use syringe or cartridge would remove benzyl alcohol exposure but would require a different container-closure system, fill-finish process, packaging configuration, and in-use stability package.

Citrate buffer

Citric acid and sodium citrate control pH and help maintain chemical stability. The buffer also affects injection tolerability, protein or peptide aggregation behavior, and compatibility with the primary container.

For a chronic injectable product, the formulation target is not only chemical stability. It must also control:

• Local injection-site irritation
• Peptide adsorption to container surfaces
• Visible and subvisible particles
• Compatibility with silicone oil or coated syringe components
• Stability during transport excursions
• Extractables and leachables from elastomers and plastics

Any reformulation that changes citrate concentration or pH would require comparative stability, local tolerance, and potentially clinical bridging work.

Hydrochloric acid and water for injection

Hydrochloric acid is used for pH adjustment rather than as a functional bulk excipient. Water for injection is the vehicle. These materials are unlikely to create independent commercial differentiation, but they remain relevant to manufacturing robustness, pH control, sterility assurance, and global supply qualification.

What formulation opportunities exist for Imcivree?

The most attractive opportunities involve delivery format and patient usability rather than a new excipient alone.

Opportunity	Commercial rationale	Main technical barrier
Preservative-free single-dose syringe	Eliminates benzyl alcohol and reduces handling steps	Higher packaging cost and more units per treatment period
Prefilled pen	Improves dose selection and home administration	Device compatibility, dose accuracy, and human-factors validation
Cartridge-based injector	Supports chronic self-administration and refill models	Container-closure and formulation-device interaction
Higher-concentration solution	Reduces injection volume	Dose accuracy, tolerability, viscosity, and regulatory bridging
Longer room-temperature stability	Reduces cold-chain burden	Accelerated stability and degradation control
Low-sorption container system	Limits peptide loss and potency variability	Material selection and extractables testing
Pediatric low-dose presentation	Improves accuracy at the lower end of weight-based dosing	Manufacturing complexity and launch economics
Electronic dose-tracking device	Supports adherence and specialty-pharmacy monitoring	Digital health integration and cybersecurity requirements

Preservative-free pediatric formulation

This is the clearest excipient-led opportunity. Imcivree is used in children as young as 2 years under the expanded FDA labeling, while the marketed multidose vial relies on benzyl alcohol. A preservative-free formulation could use a single-dose vial, prefilled syringe, or cartridge.

Potential benefits include lower preservative exposure, improved suitability for pediatric use, and a simpler product narrative for physicians and caregivers. The main tradeoff is cost. A single-dose configuration increases glass, stopper, labeling, secondary packaging, and fill-finish requirements.

A patentable formulation platform could focus on a preservative-free aqueous setmelanotide composition with defined pH, citrate concentration, container material, and stability profile. Broad composition claims may face prior-art pressure, so commercial value would likely depend on narrow, measurable performance claims.

Pen and cartridge delivery

The current vial format requires the caregiver to withdraw a weight-based dose using a syringe. A pen could reduce preparation steps and dosing errors, particularly for pediatric patients receiving small volumes.

A viable pen strategy would need to address:

• Accurate delivery of doses below 0.1 mL
• Priming and dead-volume losses
• Peptide adsorption to the cartridge or needle pathway
• Dose-setting increments
• Stability after cartridge entry
• Compatibility with refrigeration and handling excursions
• Usability by caregivers with limited injection experience

A device patent may protect the dose-setting mechanism, cartridge configuration, needle interface, or combination of device and formulation. The combination could provide stronger commercial protection than an excipient patent alone.

Higher-strength formulations

The marketed 10 mg/mL solution already permits relatively small injection volumes for many patients. A higher-strength formulation, such as 20 mg/mL, could reduce volume further and support pen delivery. The commercial case is strongest where the dose approaches the upper end of the approved range or where injection-site discomfort limits adherence.

The technical risks are material. Increasing concentration can raise aggregation, viscosity, adsorption, particulate formation, and injection-site tolerability concerns. A higher-strength product would also require dose-conversion controls to prevent medication errors.

A 505(b)(2) strategy could be relevant for a new concentration, device, or dosage form if the sponsor relies in part on FDA’s findings for the existing Imcivree product. The regulatory pathway would depend on the extent of formulation and device changes and the data required to establish safety, efficacy, and product performance.[4]

How strong is the Imcivree excipient and formulation patent opportunity?

The strongest IP positions are likely to come from narrowly defined formulation and product-by-process claims rather than generic claims covering citrate, benzyl alcohol, or an aqueous peptide solution.

Potential claim categories include:

1. Setmelanotide compositions with specified pH and citrate concentrations.
2. Preservative-free compositions with defined degradation limits.
3. Compositions that reduce aggregation or adsorption during storage.
4. Container-closure systems that maintain potency and particulate specifications.
5. Prefilled syringes or cartridges containing setmelanotide.
6. Pen injectors configured for weight-based or dose-increment administration.
7. Manufacturing methods that improve yield, purity, or stability.
8. Stability claims covering defined temperature excursions.
9. Pediatric dosage forms with specific concentration and delivery characteristics.

Patent strength depends on whether the claims require measurable technical performance. A claim limited to the use of a conventional buffer may be vulnerable to obviousness arguments. A claim tied to unexpected stability, reduced particulate formation, improved dose accuracy, or superior injection tolerability would generally have greater defensive value.

What is the Orange Book status of Imcivree?

Imcivree is approved under an NDA and is a small-molecule drug product for U.S. regulatory purposes, although setmelanotide is a synthetic peptide. It is not regulated through the biosimilar pathway. Any U.S. generic or follow-on applicant would generally evaluate an abbreviated new drug application or, for a materially different formulation or delivery system, a 505(b)(2) application.

The Orange Book is the controlling source for listed patents and regulatory exclusivity. Formulation, method-of-use, and device-related patents may affect generic launch timing if they are listed and enforceable under the Hatch-Waxman framework. Excipient-only claims do not automatically block a generic because an ANDA applicant may use different inactive ingredients if the product meets applicable safety, quality, and equivalence requirements.[5]

When does Imcivree lose exclusivity?

Imcivree’s commercial protection has several layers:

Protection layer	Relevance to Imcivree
New chemical entity exclusivity	FDA approval in 2020 created an initial period of statutory exclusivity
Orphan-drug exclusivity	Genetic obesity indications can receive orphan-drug protection where statutory criteria are met
Pediatric exclusivity	May add six months if FDA requirements are completed
Orange Book patents	Can delay or complicate ANDA approval and launch
Formulation patents	May protect improved presentations after the base product
Method-of-use patents	May cover genetically defined patient populations or dosing methods
Device patents	May protect pens, cartridges, or combination products
Trade secrets	Can protect manufacturing, purification, and fill-finish know-how

Orphan-drug exclusivity is indication-specific. It does not necessarily prevent approval of a competitor for a different disease or patient population. Patent expiration dates must be evaluated patent by patent, including terminal disclaimers, patent-term adjustment, patent-term extension, and pediatric exclusivity.

What generic entry risks exist for Imcivree?

Generic entry risk is moderate rather than immediate because the product is an injectable peptide drug for a rare population, with limited commercial volume and specialized prescribing.

The principal entry scenarios are:

Conventional injectable generic

A generic applicant could seek approval of a 10 mg/mL subcutaneous solution using a different excipient system, subject to FDA requirements. The applicant would need to address sterility, potency, impurities, particulate matter, container closure, and comparative product performance.

505(b)(2) formulation competitor

A competitor could develop a preservative-free vial, prefilled syringe, higher-concentration product, or pen. Such a product could compete without being identical to the marketed vial, but it would require a more substantial development and regulatory package.

Authorized generic or licensed alternative

The originator or a commercial partner could launch a lower-cost or alternate-channel presentation to defend against generic erosion. This strategy is more plausible if manufacturing capacity and specialty-pharmacy economics support multiple configurations.

Biosimilar risk

Biosimilar risk is not the relevant framework for Imcivree. Setmelanotide is approved as a drug under an NDA, not as a biologic under a BLA. Competitive risk should be modeled through ANDA and 505(b)(2) pathways, plus potential branded peptide competitors.

Which companies are challenging Imcivree commercially?

The competitive field includes therapies that address obesity through different biological mechanisms rather than direct setmelanotide substitution.

Competitor category	Examples	Competitive effect
MC4R pathway therapy	Setmelanotide alternatives in development	Highest mechanistic overlap
GLP-1 therapies	Semaglutide, tirzepatide and related products	Compete for obesity-treatment budgets but do not replace genotype-directed therapy
Rare-disease obesity programs	Genetic and hypothalamic obesity therapies in development	May target overlapping specialty centers
Generic or 505(b)(2) setmelanotide	Potential future entrants	Direct price and access pressure
Diagnostic companies	Genetic testing providers	Can expand or restrict identification of eligible patients

Imcivree has a clinical positioning advantage in patients with confirmed pathway defects because it is targeted to the underlying melanocortin signaling deficiency. Its addressable population is constrained by genetic diagnosis, payer criteria, and specialist access. Expanded genetic testing is therefore commercially favorable for the product.

What licensing deals and manufacturing opportunities exist?

Public commercial value is concentrated in three partnership categories:

1. Diagnostic partnerships that increase identification of POMC, PCSK1, LEPR, and Bardet-Biedl patients.
2. Device partnerships for pens, cartridges, and dose-tracking systems.
3. Contract development and manufacturing partnerships for sterile peptide filling, preservative-free presentations, and regional supply.

Excipient suppliers can pursue long-term supply agreements for pharmaceutical-grade citrate components, preservative systems, low-sorption elastomers, and specialized prefilled-device materials. The most defensible opportunity is a qualified formulation-plus-container system supported by stability and compatibility data.

Manufacturing barriers include peptide purity control, control of oxidation and degradation products, sterile fill-finish capacity, low-volume dosing accuracy, and cold-chain distribution. A supplier that solves these constraints can obtain stronger negotiating leverage than a commodity excipient provider.

How does Imcivree compare with competing obesity products?

Imcivree differs from GLP-1 products in three commercial respects:

Factor	Imcivree	GLP-1 obesity products
Patient selection	Genetically defined obesity	Broad obesity populations
Primary value proposition	Targeted treatment of MC4R-pathway deficiency	Broad weight reduction and metabolic benefits
Commercial scale	Rare-disease market	Large primary-care and specialty market
Formulation opportunity	Pediatric dosing, preservative-free injection, device usability	Pen systems, extended dosing intervals, combination products
Substitution risk	Limited direct substitution	Strong budget and prescribing competition

Imcivree’s smaller population reduces volume leverage but supports specialty-drug pricing and focused distribution. Excipient innovation should therefore prioritize safety, adherence, and presentation differentiation rather than manufacturing cost alone.

Key Takeaways

• Imcivree is a 10 mg/mL multidose subcutaneous setmelanotide injection using benzyl alcohol and citrate buffering components.
• The leading excipient opportunity is a preservative-free pediatric presentation.
• Prefilled syringes, cartridges, and pens could improve dose accuracy and caregiver usability.
• Higher-strength formulations may reduce injection volume but require careful control of aggregation, viscosity, adsorption, and tolerability.
• Imcivree faces ANDA and 505(b)(2) risks, not conventional biosimilar risk.
• Formulation, container-closure, device, and manufacturing patents may provide longer-lived protection than basic excipient claims.
• Diagnostic expansion is a major commercial driver because the product requires genetically defined patient selection.
• The best supplier opportunities combine excipient supply with container, device, stability, or fill-finish know-how.

FAQs

Can Imcivree be reformulated without benzyl alcohol?

Yes. A preservative-free version could use a single-dose vial, prefilled syringe, or cartridge. The change would require new stability, sterility, container-closure, and regulatory data.

Is setmelanotide a biologic for biosimilar purposes?

No. Imcivree is approved under an NDA. Competitive products would generally pursue generic or 505(b)(2) pathways rather than the biosimilar pathway.

Could a different excipient system support an Imcivree generic?

Yes. An ANDA applicant may use different inactive ingredients if FDA requirements for safety, quality, pharmaceutical equivalence, and product performance are met.

Would a prefilled pen be patentable for Imcivree?

Potentially. Protection would depend on novel and non-obvious features involving dose accuracy, cartridge configuration, peptide compatibility, delivery mechanics, or human-factors performance.

What is the highest-value excipient strategy for Imcivree?

A preservative-free, low-volume, pediatric-compatible formulation integrated into a prefilled syringe or pen has the strongest combined commercial, clinical, and IP rationale.

References

1. U.S. Food and Drug Administration. (2020). FDA approves treatment for chronic weight management in patients with rare genetic diseases. https://www.fda.gov
2. U.S. Food and Drug Administration. (2022). FDA approves treatment for chronic weight management in patients with Bardet-Biedl syndrome. https://www.fda.gov
3. Rhythm Pharmaceuticals, Inc. (2024). Imcivree (setmelanotide) injection prescribing information.
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm